Autosomal dominant C1149R von Willebrand disease: Phenotypic findings and their implications

Haematologica

Volumn 94, Issue 5, 2009, Pages 679-686

  Pérez Rodríguez, Almudena ^a,b   García Rivero, Aranzazu ^c   Lourés, Esther ^a,b   López Fernández, Maria Fernanda ^a,b   Rodríguez Trillo, Angela ^a,b   Batlle Fonrodona, Francisco Javier ^a,b  

^a HOSPITAL JUAN CANALEJO   (Spain)

^b UNIVERSITY OF SANTIAGO DE COMPOSTELA   (Spain)

^c Centro Oncologico de Galicia   (Spain)

Author keywords

C1149R von Willebrand disease; Desmopressin; Platelet von Willebrand factor; Von Willebrand factor; VWD type 2A (IIE)

Indexed keywords

COLLAGEN; DESMOPRESSIN; RISTOCETIN; UNCLASSIFIED DRUG; VON WILLEBRAND FACTOR; VON WILLEBRAND FACTOR ANTIGEN; VON WILLEBRAND FACTOR C1149R; VON WILLEBRAND FACTOR RISTOCETIN COFACTOR;

ARTICLE; AUTOSOMAL DOMINANT DISORDER; BLEEDING; CLINICAL ARTICLE; CONTROLLED STUDY; DIAGNOSTIC VALUE; DISEASE CLASSIFICATION; FEMALE; GENE MUTATION; HUMAN; HUMAN CELL; MALE; MOLECULAR WEIGHT; PHENOTYPE; SYNDROME DELINEATION; VON WILLEBRAND DISEASE; VON WILLEBRAND DISEASE TYPE 2A;

BLOOD PLATELETS; DEAMINO ARGININE VASOPRESSIN; ELECTROPHORESIS, AGAR GEL; FEMALE; GENES, DOMINANT; HUMANS; MALE; MOLECULAR WEIGHT; MUTATION; PHENOTYPE; PROTEIN MULTIMERIZATION; TIME FACTORS; VON WILLEBRAND DISEASE; VON WILLEBRAND FACTOR;

EID: 66049129490     PISSN: 03906078     EISSN: 15928721     Source Type: Journal    
DOI: 10.3324/haematol.2008.003301     Document Type: Article

References (40)

1. Weiss HJ, Sussman II, Hoyer LW. Stabilization of factor VIII in plasma by the von Willebrand factor. Studies on posttransfusion and dissociated factor VIII and in patients with von Willebrand's disease. J Clin Invest 1977;60:390-404.
2. Sadler JE. Biochemistry and genetics of von Willebrand factor. Annu Rev Biochem 1998;67:395-424. (Pubitemid 28411134)
3. Sadler JE, Budde U, Eikenboom JC, Favaloro EJ, Hill FG, Holmberg L, et al. Update on the pathophysiology and classification of von Willebrand disease: a report of the Subcommittee on von Willebrand Factor. J Thromb Haemost 2006;4: 2103-2114
4. Batlle J, Perez-Rodriguez A, Franqueira MD, Lopez-Fernandez MF. Type 2M von Willebrand disease: a variant of type 2A? J Thromb Haemost 2008;6:388-390
5. Eikenboom JC, Matsushita T, Reitsma PH, Tuley EA, Castaman G, Briet E, et al. Dominant type 1 von Willebrand disease caused by mutated cysteine residues in the D3 domain of von Willebrand factor. Blood 1996;88:2433-2441
6. Bodo I, Katsumi A, Tuley EA, Eikenboom JC, Dong Z, Sadler JE. Type 1 von Willebrand disease mutation Cys1149Arg causes intracellular retention and degradation of heterodimers: a possible general mechanism for dominant mutations of oligomeric proteins. Blood 2001;98:2973-2979
7. Tjernberg P, Vos HL, Castaman G, Bertina R, Eikenboom JC. Dimerization and multimerization defects of von Willebrand factor due to mutated cysteine residues. J Thromb Haemost 2004;2:257-265 (Pubitemid 40186039)
8. Schooten CJ, Tjernberg P, Westein E, Terraube V, Castaman G, Mourik JA, et al. Cysteine-mutations in von Willebrand factor associated with increased clearance. J Thromb Haemost 2005;3:2228-2237
9. Batlle J, Lopez Fernandez MF, Lasierra J, Fernandez Villamor A, Lopez Berges C, Lopez Borrasca A, et al. Von Willebrand disease type IIC with different abnormalities of von Willebrand factor in the same sib-ship. Am J Hematol 1986;21:177-188
10. Holmberg L, Karpman D, Isaksson C, Kristoffersson AC, Lethagen S, Schneppenheim R. Ins405AsnPro mutation in the von Willebrand factor propeptide in recessive type 2A (IIC) von Willebrand's disease. Thromb Haemost 1998;79:718-722 (Pubitemid 28163841)
11. Tosetto A, Rodeghiero F, Castaman G, Goodeve A, Federici AB, Batlle J, et al. A quantitative analysis of bleeding symptoms in type 1 von Willebrand disease: results from a multicenter European study (MCMDM-1 VWD). J Thromb Haemost 2006;4:766-773
12. Batlle J, López Fernández MF. Laboratory assays for von Willebrand factor. In: Zimmerman TS, Ruggeri ZM, eds. Coagulation and bleeding disorders: the role FVIII and von Willebrand factor. New York: Marcel Dekker, Inc. 1989. p. 325-342
13. Budde U, Schneppenheim R, Plendl H, Dent J, Ruggeri ZM, Zimmerman TS. Luminographic detection of von Willebrand factor multimers in agarose gels and on nitrocellulose membranes. Thromb Haemost 1990;63:312-315 (Pubitemid 20128202)
14. Dent JA, Galbusera M, Ruggeri ZM. Heterogeneity of plasma von Willebrand factor multimers resulting from proteolysis of the constituent subunit. J Clin Invest 1991; 88:774-782
15. Castaman G, Lattuada A, Ruggeri M, Tosetto A, Mannucci PM, Rodeghiero F. Platelet von Willebrand factor abnormalities in myeloproliferative syndromes. Am J Hematol 1995;49:289-293
16. Haberichter SL, Jozwiak MA, Rosenberg JB, Christopherson PA, Montgomery RR. The von Willebrand factor propeptide (VWFpp) traffics an unrelated protein to storage. Arterioscler Thromb Vasc Biol 2002;22:921-926 (Pubitemid 34655218)
17. Haberichter SL, Balistreri M, Christopherson P, Morateck P, Gavazova S, Bellissimo DB, et al. Assay of the von Willebrand factor (VWF) propeptide to identify patients with type 1 von Willebrand disease with decreased VWF survival. Blood 2006;108:3344-3351
18. Haberichter SL, Castaman G, Budde U, Peake I, Goodeve A, Rodeghiero F, et al. Identification of type 1 von Willebrand disease patients with reduced von Willebrand factor survival by assay of the VWF propeptide in the European study: molecular and clinical markers for the diagnosis and management of type 1 VWD (MCMDM-1VWD). Blood 2008;111:4979-4985
19. Goodeve A, Eikenboom J, Castaman G, Rodeghiero F, Federici AB, Batlle J, et al. Phenotype and genotype of a cohort of families historically diagnosed with type 1 von Willebrand disease in the European study, Molecular and Clinical Markers for the Diagnosis and Management of Type 1 von Willebrand Disease (MCMDM-1VWD). Blood 2007;109:112-121
20. Batlle J, Lopez-Fernandez MF, Lopez-Borrasca A, Lopez-Berges C, Dent JA, Berkowitz SD, et al. Proteolytic degradation of von Willebrand factor after DDAVP administration in normal individuals. Blood 1987;70:173-176
21. Mancuso DJ, Tuley EA, Westfield LA, Worrall NK, Shelton-Inloes BB, Sorace JM, et al. Structure of the gene for human von Willebrand factor. J Biol Chem 1989;264:19514-19527
22. Zimmerman TS, Dent JA, Ruggeri ZM, Nannini LH. Subunit composition of plasma von Willebrand factor. Cleavage is present in normal individuals, increased in IIA and IIB von Willebrand disease, but minimal in variants with aberrant structure of individual oligomers (types IIC, IID, and IIE). J Clin Invest 1986;77:947-951
23. Federici AB, Mazurier C, Berntorp E, Lee CA, Scharrer I, Goudemand J, et al. Biologic response to desmopressin in patients with severe type 1 and type 2 von Willebrand disease: results of a multicenter European study. Blood 2004;103:2032-2038
24. Castaman G, Lethagen S, Federici AB, Tosetto A, Goodeve A, Budde U, et al. Response to desmopressin is influenced by the genotype and phenotype in type 1 von Willebrand disease (VWD): results from the European Study MCMDM-1VWD. Blood 2008;111:3531-3539
25. Castaman G, Eikenboom JC, Missiaglia E, Rodeghiero F. Autosomal dominant type 1 von willebrand disease due to G3639T mutation (C1130F) in exon 26 of von Willebrand factor gene: description of five Italian families and evidence for a founder effect. Br J Haematol 2000;108:876-879 (Pubitemid 30304526)
26. Budde U, Schneppenheim R, Eikenboom J, Goodeve A, Will K, Drewke E, et al. Detailed von Willebrand factor multimer analysis in patients with von Willebrand disease in the European study, molecular and clinical markers for the diagnosis and management of type 1 von Willebrand disease (MCMDM-1VWD). J Thromb Haemost 2008; 6:762-771
27. Gavazova S, Gill JC, Scott JP, Hillery CA, Friedman KD, Wetzel N, et al. A mutation in the D4 domain of von Willebrand factor (VWF) results in a variant of type 1 von Willebrand disease with accelerated in vivo VWF clearance. Blood 2002;100:128a [abstract].
28. Nossent AY, Eikenboom JC, Vos HL, Bakker E, Tanis BC, Doggen CJ, et al. Haplotypes encoding the factor VIII 1241 Glu variation, factor VIII levels and the risk of venous thrombosis. Thromb Haemost 2006;95:942-948
29. Batlle J, Lopez Fernandez MF, Campos M, Justica B, Berges C, Navarro JL, et al. The heterogeneity of type IIA von Willebrand's disease: studies with protease inhibitors. Blood 1986;68:1207-1212
30. Lenting PJ, Neels JG, van den Berg BM, Clijsters PP, Meijerman DW, Pannekoek H, et al. The light chain of factor VIII comprises a binding site for low density lipoprotein receptor-related protein. J Biol Chem 1999;274:23734-23739
31. Ellies LG, Ditto D, Levy GG, Wahrenbrock M, Ginsburg D, Varki A, et al. Sialyltransferase ST3Gal-IV operates as a dominant modifier of hemostasis by concealing asialoglycoprotein receptor ligands. Proc Natl Acad Sci USA 2002;99:10042-10047
32. Lenting PJ, Westein E, Terraube V, Ribba AS, Huizinga EG, Meyer D, et al. An experimental model to study the in vivo survival of von Willebrand factor. Basic aspects and application to the R1205H mutation. J Biol Chem 2004;279:12102-12109
33. Cumming A, Grundy P, Keeney S, Lester W, Enayat S, Guilliatt A, et al. An investigation of the von Willebrand factor genotype in UK patients diagnosed to have type 1 von Willebrand disease. Thromb Haemost 2006;96:630-641
34. Peake I, Goodeve A. Type 1 von Willebrand disease. J Thromb Haemost 2007;5 (Suppl 1):7-11. (Pubitemid 46964283)
35. James PD, Notley C, Hegadorn C, Leggo J, Tuttle A, Tinlin S, et al. The mutational spectrum of type 1 von Willebrand disease: Results from a Canadian cohort study. Blood 2007;109:145-154
36. Favaloro EJ, Bonar R, Marsden K. Lower limit of assay sensitivity: an under recognised and significant problem in von Willebrand disease identification and classification. Clin Lab Sci 2008;21:178-183
37. Favaloro EJ. Detailed von Willebrand factor multimer analysis in patients with von Willebrand disease in the European study, molecular and clinical markers for the diagnosis and management of type 1 von Willebrand disease (MCMDM-1VWD): a rebuttal. J Thromb Haemost 2008;6:1999-2001.
38. Schneppenheim R, Budde U, Ruggeri ZM. A molecular approach to the classification of von Willebrand disease. Best Pract Res Clin Haematol 2001;14:281-288 (Pubitemid 32677080)
39. van Vliet HH, Kappers-Klunne MC, Leebeek FW, Michiels JJ. PFA-100 monitoring of von Willebrand factor (VWF) responses to DDAVP and FVIII/VWF concentrate substitution in von Willebrand disease type 1 and 2. Thromb Haemost 2008;100:462-468
40. Favaloro EJ. A better approach to monitoring of therapy in von Willebrand disease? Thromb Haemost 2008;100:371-373